⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AKTS News
Aktis Oncology, Inc. Common stock
Asahi Kasei Therapeutics Announces Late-Breaking Oral and Poster Presentations at IDWeek 2026
prnewswire.com
AKTS
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
globenewswire.com
AKTS
Form 8-K
sec.gov
AKTS
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
globenewswire.com
AKTS
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
globenewswire.com
AKTS
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
globenewswire.com
AKTS
Form 8-K
sec.gov
AKTS
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
globenewswire.com
AKTS
Aktis Oncology to Present at the BofA Securities Health Care Conference
globenewswire.com
AKTS
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
globenewswire.com
AKTS